Quote this publication Share Print

VARUBY (rolapitant), NK1 receptor antagonist antiemetic

GASTROENTEROLOGY ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Jan 18 2018

Reason for request

Inclusion

No clinical benefit demonstrated in the prevention of delayed nausea and vomiting after highly and moderately emetogenic chemotherapies

 

  • VARUBY has Marketing Authorisation in prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapies.
  • Its benefit compared with placebo has not been demonstrated in prevention of acute nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapies, when acute nausea and vomiting are a predisposing factor to delayed nausea and vomiting.
  • In the context of a highly or moderately emetogenic chemotherapy, the available data do not make it possible to assess the benefit of VARUBY in the strategy for prevention of nausea and vomiting which includes: setron + corticosteroid + NK1 receptor antagonist. The impact on morbidity and on quality of life have not been demonstrated to date.
  • VARUBY should be reserved for patients who cannot receive triple therapy based on another NK1 receptor antagonist.

 

 


Actual benefit

Faible

-


Improvement in actual benefit

V (absence)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments